Business Model Breakdown
How electroCore, Inc. Makes Money
ECOR
Market Cap
$53M
Annual Revenue
$32M
Profit Margin
0.0%
Employees
73
The Short Version
electroCore, Inc. develops and commercializes gammaCore, a unique, non-invasive, handheld medical device that uses mild electrical stimulation to modulate the vagus nerve in the neck. This device is FDA-approved for the acute and preventative treatment of certain primary headache disorders, including migraine and cluster headaches. The company generates revenue by selling or leasing these prescription-based devices and associated components to patients (through healthcare providers), clinics, and healthcare systems, offering a drug-free alternative for pain management.
Where the Revenue Comes From
Sales and leasing of gammaCore devices (~100% of revenue)
Who buys: Patients suffering from headache disorders (via prescription), neurologists, pain management clinics, and other healthcare providers.
Why It Works (Competitive Advantages)
- ✔Patented, FDA-approved gammaCore non-invasive vagus nerve stimulator (nVNS) technology.
- ✔High gross margins (86-87%) indicate strong product value and cost efficiency.
- ✔Addresses a large and underserved market for headache disorders with a non-pharmacological solution.
Economic Moat: Narrow (Intangible Assets/IP (Patents, FDA approval for gammaCore), Switching Costs (Physician and patient familiarity/comfort with an effective device))
What Our Analysis Says
DVR Score as of April 10, 2026
electroCore's gammaCore device targets a vast market for headache disorders with a patented, FDA-approved, non-invasive solution, demonstrating solid FY2025 revenue growth of 26% YoY to ~$32M and impressive gross margins of 86-87%. This strategic vision and operational efficiency are compelling. However, these positives are severely undermined by critical financial distress: a substantial GAAP net loss of $14.0M in FY2025 against an extremely limited cash balance of $11.6M as of December 31, 2025. This high cash burn rate presents an imminent threat of insolvency or significant shareholder dilution, despite positive analyst sentiment and recent IP expansion. While a leadership transition has occurred, the core funding challenge remains. Without a near-term, substantial financial inflection point or a major funding event, the path to 10x growth within 3-5 years remains highly improbable due to existential funding constraints. The score is consistent with the previous analysis due to no material change in the critical cash position vs. burn rate.